Speed to market wont guarantee success in todays launch environment. Anticipating what prescribers, patients and payers will ...

With the wrong architecture in place, AI algorithms can nudge biopharmaceutical developers toward unpredicted and misaligned ...

Biotech is the most honest leadership environment in the world. Science does not soften bad news. Markets do not wait for leaders to feel ready. And the pressure does not lift between a failed trial, ...

In the pharmaceutical industry, where innovation cycles span decades and billions of dollars hinge on patent protection, the relationship between a company and its external intellectual property ...

Life sciences startups have long felt the gravitational pull of Boston and San Francisco when looking to raise capital, expand, and recruit talent. These two coastal regions, with an established ...

For many families living with rare pediatric diseases, hope often arrives quietly — after years of uncertainty, missed diagnoses, and being told that treatment may never come in time. For Lindsey ...

Here’s my thesis: biotech remains one of the most exciting and promising industries in the world, driven by the inescapable reality that nothing matters more than our health. Despite the fact that in ...

Pharmaceutical companies are responsible for providing accurate, balanced, non-promotional information about their products to both patients and healthcare providers. In these points of contact, ...

Empirical research comparing corporate and academic spin-offs consistently shows that corporate-originated ventures outperform their academic counterparts in terms of growth and survival. This ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

As the life sciences industry grapples with the demands of AI and the need to integrate real-world evidence into increasingly complex pipelines, the FAIR data principles — Findable, Accessible, ...

We are now well into what is often called the “psychedelic renaissance,” and the field has made genuine progress alongside all the early excitement. Many groups new to the realities of FDA oversight ...